Breaking Down Barriers to Access and Affordability of Specialty and Rare-Disease Treatments
Bio-process Intl • Wed Sep 10 2025
By Dea Belazi, AscellaHealth
Successfully achieving a primary endpoint in a rare-disease trial is a significant milestone for biopharmaceutical research teams. After years of investigation and meticulous clinical trials, it is natural for organizations to believe that the hardest part is behind them. However, developers working to improve clinical outcomes and quality of life for patients with debilitating rare conditions soon face a new challenge: overcoming the barriers to treatment access.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.